Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about screening for bladder and other urothelial cancers. This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board.
Information about the following is included in this summary:
This summary is intended as a resource to inform clinicians and other health professionals about currently available screening modalities for bladder and other urothelial cancers. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in reporting the evidence of benefit and potential harms associated with each screening modality. It does not provide formal guidelines or recommendations for making health care decisions. Information in this summary should not be used as a basis for reimbursement determinations.
This summary is also available in a patient version, which is written in less technical language.
Note: Separate PDQ summaries on Bladder Cancer Treatment and Levels of Evidence for Cancer Screening and Prevention Studies are also available.
There is inadequate evidence to determine whether screening for bladder and other urothelial cancers has an impact on mortality.
Based on fair evidence, screening for bladder and other urothelial cancers would result in unnecessary diagnostic procedures with attendant morbidity.
Description of Evidence
Incidence and Mortality
Bladder cancer is the fourth most commonly diagnosed malignancy in men in the United States and the ninth most commonly diagnosed malignancy in U.S. women. It is estimated that 68,810 new cases of bladder cancer are expected to occur in the United States in 2008. 
Bladder cancer is diagnosed almost twice as often in whites as in blacks of either sex. The incidence of bladder cancer among other ethnic and racial groups in the United States falls between that of blacks and whites. The incidence of bladder cancer increases with age. Approximately 80% of newly diagnosed cases in both men and women occur in people aged 60 years and older. 
Since the 1950s, the incidence of bladder cancer has risen by approximately 50%. It is to be anticipated that, with the aging of the U.S. population, this trend will continue. In contrast, there has been a decrease of approximately 33% in bladder cancer mortality during the same interval (National Cancer Institute’s Surveillance, Epidemiology, and End Results program, 1973–1997). It is estimated that 14,100 Americans will die of bladder cancer in 2008. 
The age-adjusted mortality from bladder cancer has decreased in all races and sexes over the past 30 years,  but blacks and women have a disproportionately higher mortality rate than that of white males. These changes may reflect earlier diagnosis, better therapy, less exposure to carcinogens, or some combination of these factors.
More than 90% of cancers in the bladder are transitional cell carcinomas (TCC), also called urothelial cancer. Other important histologic types include squamous cell carcinoma and adenocarcinoma. Urothelial cancer can also rarely develop in the lining of the renal pelvis, ureter, prostate, and urethra.
There are no definitive studies on the prevention of bladder or other urothelial cancers. Reduction in environmental and occupational exposures would presumably reduce urothelial cancer risk. Differences in age, gender, race, and geographic distribution may reflect differences in environmental and occupational exposure to possible toxicants. Relevant exposures include chemical exposures; cigarette smoking; infection with bacteria, parasitic fungi, or viruses; harboring bladder calculi; and treatment with certain chemotherapeutic agents. 
Several populations with a variety of exposures appear to be at higher risk of developing bladder cancer. By far the greatest known environmental risk factor in the general population is tobacco, especially cigarette smoking, with individuals who smoke having a fourfold to sevenfold increased risk of developing bladder cancer than individuals who have never smoked.    Risk is reduced with cessation of smoking, but a relatively small decrease in incidence is seen for the first 5 to 7 years after cessation. Even after 10 years, the risk of an individual developing bladder cancer is still almost twice that of an individual who has never smoked.
Among the chemicals implicated in smoking-induced bladder cancer are aminobiphenyl and its metabolites.  It is possible that inherited and inducible enzymes are important in the activation and detoxification of aminobiphenyls and other putative bladder carcinogens. These enzymes include N-acetyltransferase 2 (NAT2),  cytochrome P450 1A2 (CYT 1A2),  and glutathione S-transferase M 1.  Several studies have indicated that specific genotypes and phenotypes of these enzymes and their activities, particularly in the liver and urothelium, are associated with susceptibility to smoking-induced bladder cancer and bladder cancer induced by other aryl amines, particularly in industrially exposed populations.       Not all of these studies, however, have been well controlled for active or former smoking histories.
A variety of industrial exposures have also been implicated as risk factors for developing bladder cancer, primarily aromatic amines present in the production of dyes and benzidine and its derivatives;  combustion gases and soot from coal, possibly chlorinated aliphatic hydrocarbons;  chlorination by-products in heated water;  and certain aldehydes (e.g., acrolein used in chemical dyes and in the rubber and textile industries). 
Occupations reported to be associated with an increased risk of bladder cancer include those that involve organic chemicals such as dry cleaners, paper manufacturers, rope and twine makers, and workers in apparel manufacturing.    
It is estimated that 5% to 15% of patients in the United States who eventually die from bladder cancer will have strong exposure histories to the above-named environmental factors (other than smoking). 
The use of contaminated Chinese herbs is also reported to be a risk factor. The prime carcinogen in these herbs appears to be aristolochic acid (AA) extracted from species of Aristolochia.  Because of the diversity of Chinese herbal regimens used in addition to AA, other unidentified phytotoxins may also play a role.  The chronic nephropathy associated with ingestion of herbs contaminated with A. fangchi has been linked to urothelial carcinoma of the renal pelvis and ureter. Herbs with A. fangchi are banned from Belgium, Canada, Australia, and Germany but are still available in the United States. 
Ingestion of large quantities of arsenic in well water has also been associated with numerous malignancies, including TCC of the bladder.   Similar endemic pockets of bladder cancer are found in other regions with high arsenic concentrations in drinking water.  In South Taiwan, arsenic blackfoot disease is endemic.
Additional risk factors associated with more aggressive forms of bladder cancer include prolonged exposures to urinary foreign bodies and infections;  neuropathic bladder and associated indwelling catheters;   Schistosoma haematobium bladder infections (Bilharzial bladder cancer);  exposure to the cancer chemotherapy agent cyclophosphamide     and perhaps other alkylating agents, such as ifosfamide (although the use of mesna in conjunction with these agents may reduce the incidence);  and pelvic radiation therapy for other malignancies.    Renal transplant recipients appear to have an increased incidence of bladder cancer. 
Urothelial tumors other than TCC include adenocarcinoma, squamous cell carcinoma, and metastatic adenocarcinoma. Risks for squamous cell tumors in the bladder include indwelling catheters,   and S. haematobium cystitis.
Adenocarcinomas account for less than 2% of primary bladder cancers, including metastases from the rectum, stomach, endometrium, breast, prostate, and ovary. 
Although occasional familial clusters have been anecdotally reported    and bladder cancer (as well as upper urinary tract TCC) is part of the Lynch family cancer syndrome II,  there is no evidence that tendencies towards developing bladder cancer are inherited. 
Seventy percent of patients with bladder cancer have superficial disease at presentation.  Hematuria is the most common presenting sign, occurring in about 90% of cases. Hematuria may be intermittent, so a urinalysis without red blood cells does not exclude a diagnosis of urothelial cancer. In patients with macroscopic hematuria, the reported rates of bladder cancer range from 13% to 34.5%.    Other presenting symptoms include dysuria, urinary frequency or urgency, and less commonly, flank pain secondary to obstruction, and pain from pelvic invasion or bone metastases. Diagnosis and staging usually begin with cystoscopy. Full evaluation of the upper and lower urinary tract is required. 
More than 90% of bladder cancers diagnosed in the United States are pure TCCs or TCCs mixed with other histologies, primarily squamous cell carcinoma, adenocarcinoma, or both. An additional 3% to 4% are pure squamous cell carcinomas, which are approximately twice as likely to occur in women compared with men. Squamous cell carcinomas also represent a greater proportion of bladder cancers occurring in individuals who have S. haematobium infections of the bladder or who have histories of long-term indwelling urinary catheters, bladder stones, or recurrent bladder infections.   
Both the grade and stage at diagnosis of TCC have extremely important prognostic and therapeutic implications. Nontransitional cell histologies, however, all behave very aggressively and are less responsive to treatments other than extirpative surgery.  The prognoses of patients and the choice of treatments depend on the aggressiveness and grade of the tumor.
Grade and Stage of Newly Diagnosed Bladder Cancer in an Unscreened Population
Although the critical nature of the histologic grade and stage of index lesions for individual prognosis and management decisions has been well recognized for many years, only one contemporary study has attempted to evaluate grade and stage in newly diagnosed bladder tumors in a population-based setting.  In this study, 89% of all newly diagnosed bladder cancers in men aged 50 years and older reported to the state of Wisconsin tumor registry in calendar year 1988 had blocks and slides reviewed by a single pathologist who did not know the original diagnosis. Fifty-seven percent of specimens were grade I or II, stage Ta or T1 TCCs; 19% were grade III, stage Ta or T1 (or TIS) TCCs; and 24% were muscularis propria invading or deeper (stage T2+), almost all of which were grade III lesions or of nontransitional cell histologies. Because of Wisconsin’s small population of black males aged 50 years and older (fewer than 3% of all bladder cancers occurred in nonwhites),  differences in grade and stage at presentation between blacks and whites could not be determined. Similarly, this study did not look at females or at males younger than 50 years. No other population-based studies have been published that include central pathology review of grade and stage of bladder tumors at presentation, with subdivisions of superficial and muscle-invasive lesions. Because of variability in histologic interpretations of bladder cancers recorded by tumor registries,   the presenting grade and stage of this malignancy in Wisconsin is known only for males aged 50 years and older.
Almost all bladder malignancies originate on the uroepithelial surface. The majority of patients who die from bladder cancer do so from metastatic disease; treatment for metastatic bladder cancer is rarely, if ever, curative.  The overwhelming majority of patients with metastases have concomitant or prior muscularis propria (stage T2+) invading lesions.  Approximately 90% of patients with muscularis propria invading bladder cancer present with this diagnosis, however,   do not come from the much larger pool of patients with recurring superficial TCCs. The goal of screening is the early detection of bladder cancer that is destined to become muscle invading. Although one study reports that approximately 30% of patients with superficial TCC followed for 20 years will eventually die from this disease,  these data remain unconfirmed, are at odds with other reports,  and may reflect outmoded patterns of diagnosis, classification, and management.
Because bladder cancer is almost never incidentally found at autopsy, the preclinical duration in which it has not yet caused symptoms, but in which it can be detected by cystoscopy, is probably brief. This rapid growth rate is supported by clinical experience  and implies that screening would have to be performed at frequent intervals.
Cystoscopy and cytology
The use of cystoscopies and bladder wash/urinary cytologic examinations has proven quite successful in the surveillance and management of patients with previously treated bladder cancers.  These means are not practical in individuals without a history of bladder cancer because of expense and morbidity.
Although hematuria is the most common presenting sign of bladder cancer, most individuals with hematuria do not have bladder cancer. In the general population, the prevalence of asymptomatic gross hematuria is about 2.5% while the prevalence of asymptomatic microhematuria is about 13%.  In a recent prospective analysis of patients attending a hematuria clinic in the United Kingdom, 183 (19.2%) of the 948 patients with gross hematuria were found to have bladder cancer on cystoscopy.  In contrast, only 47 (4.8%) of the 982 patients with microhematuria were found to have bladder cancer.
One-time hematuria testing
Two groups have reported on the use of testing a single urine specimen for blood to detect urologic malignancies, serious urinary tract diseases, and bladder cancers. Both studies were performed retrospectively to ascertain information from patients who were seen at a large multispecialty clinic  or who subscribed to a large health maintenance organization (HMO) and were tested in a multiphasic screening.  Because of the retrospective nature of each study, neither was designed to specifically look for bladder cancer detection or to focus on the population at highest risk (men aged 50 years and older). Both studies concluded that single hematuria testing was not effective in diagnosing bladder cancer. A longer follow-up of the HMO study indicated that individuals with microhematuria were at a higher risk for subsequent development of muscle-invading bladder cancer, with a latency of 3.5 to 14.5 years.  There is insufficient evidence to indicate that single hematuria testing is effective in screening for bladder cancer, and there is no evidence that single hematuria testing results in reduced mortality from the disease.
Repetitive hematuria testing
Two studies using Ames Hemastix, a chemical reagent strip for hemoglobin that correlates with microscopic urinalysis in detecting hematuria,  were conducted in geographically defined (Madison, Wisconsin and Leeds, England) populations of middle-aged and elderly men using repetitive home reagent strip testing. In each program, patients were solicited from patient care registries. Men with histories of previous urologic malignancies, or known causes of hematuria, or who were noncompliant were eliminated. In the four studies performed (one pilot study and one larger study at each site), 45% to 55% of solicited individuals took part. In these studies, 1.2% to 1.3% of all participants were found to have bladder cancer (all TCC). Only 1 of the 21 patients in the first study    and none of the 26 detected in the second study had stage T2 or greater malignancy. As a limitation of repetitive hematuria screening in a general population of men aged 50 years and older, more than 90% of individuals with positive tests upon initial work-up were found not to have bladder cancer.  In the Wisconsin hematuria screening studies, all patients who were hematuria positive with negative work-ups or who were found to have no serious disease were followed for at least 24 months, with no findings of developing bladder cancer. Similarly, at least 18 months after their last testing, no screening participant (with or without hematuria) had died of bladder cancer. It is possible that longer follow-up is necessary to prove that these participants did not have bladder cancer;  however, such studies are not available. The relatively low positive predictive value of repetitive hematuria testing (7.6% for bladder cancer and 11.6% for all malignancies)    raises questions about the practicality of this mode of screening.
The accuracy of voided urine cytology in detecting bladder cancer has been evaluated primarily in patients with histories of bladder cancer who are undergoing cystoscopic surveillance, or as a routine test performed in all patients attending a large urology office in a multispecialty clinic. In the studies of patients with histories of bladder cancer, voided urinary cytology was effective in diagnosing 20% to 40% of grade I TCCs, 20% to 50% of grade II malignancies, and 60% to 80% of grade III/TIS cancers.   Although such studies were not performed in patients without either hematuria or histories of recurrent bladder tumors, a major concern for screening purposes is the lack of sensitivity for well-differentiated and moderately differentiated TCCs and the large proportion of specimens in which an insufficient number of cells were present for any cytologic diagnosis to be offered. Although false positives were exceedingly rare, the lack of sensitivity even in this highly suspect population make voided urine cytology an inappropriate test for screening the general population. No studies have looked at outcome of cytologic screening on disease-related mortality in a nonindustrially exposed population. Outcomes of patients screened at the urology clinic are also not available. 
The outcomes of men diagnosed with bladder cancer through a hematuria home screening program using a chemical reagent strip were compared with a statewide population-based sample from the Wisconsin tumor registry.  Histologic sections were blindly reviewed, and similar proportions of low-grade superficial versus high-grade or invasive cases were found; the proportion of late-stage (T2 or higher) disease was lower in the screened patients. At 24 months, 16% of tumor registry patients had died from bladder cancer (including 35% of those with grade III lesions); however, at 3 to 8 years of follow-up, no screened patient had died of bladder cancer. Whether these differences resulted from some combination of lead-time effect, overdiagnosis, or selection biases, a real screening effect cannot be determined.
The measurement of a variety of urinary antigens has been proposed, and in some cases marketed, to monitor previously diagnosed bladder cancer patients; however, the specificity and sensitivity of these markers are inadequate for screening a general population, and no prospective trials have been performed.
In populations at particularly high risk for developing bladder cancer (other than those with histories of bladder cancer), few screening studies that have assessed bladder cancer mortality have been published.     A study of annual cytology in aluminum workers exposed to coal tar pitch in Quebec showed a nearly 40% reduction in bladder cancer case-fatality 6 years after diagnosis, compared with a historical control group of workers from the same plants who were not screened;  the difference, however, was not statistically significant. Awareness of adverse outcome in the unscreened predecessors may have influenced participation in the program and workers’ awareness of symptoms, the willingness of workers and physicians to initiate diagnostic investigations based on signs and symptoms, and the compliance of workers with medical recommendations for evaluation and treatment. The brief duration of follow-up in the screened group may have artifactually improved the outcome.
No randomized controlled bladder cancer screening trials have been conducted in environmentally or industrially exposed cohorts. Completed studies have usually not had comparable control groups, have not been of sufficient sample size to show an effect on outcome, and have been of insufficient length to show a mortality benefit (or lack thereof) for the modality or modalities being assessed.   One study described the usefulness of measuring three biomarkers in voided urine for risk assessment and cancer detection in a large cohort of Chinese workers at increased risk of bladder cancer.  The workers were individually stratified, screened, monitored, and diagnosed on the basis of predefined molecular biomarker profiles. These techniques remain investigational.
1. American Cancer Society.: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008. Also available online. Last accessed May 30, 2008.
2. American Cancer Society.: Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society, 2004. Also available online. Last accessed January 21, 2008.
3. National Cancer Institute.: 1987 Annual Cancer Statistics Review. Including Cancer Trends: 1950-1985. Bethesda, Md: National Cancer Institute, 1988. NIH Publication No. 88-2789.
4. Messing EM: Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Philadelphia: Saunders, 2002, pp 2732-2773.
5. Morrison AS: Advances in the etiology of urothelial cancer. Urol Clin North Am 11(4): 557-566, 1984.
6. Burch JD, Rohan TE, Howe GR, et al.: Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44 (4): 622-8, 1989.
7. Clavel J, Cordier S, Boccon-Gibod L, et al.: Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer 44 (4): 605-10, 1989.
8. Hoffmann D, Masuda Y, Wynder EL: Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. Nature 221: 254-256, 1969.
9. Risch A, Wallace DM, Bathers S, et al.: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4 (2): 231-6, 1995.
10. Horn EP, Tucker MA, Lambert G, et al.: A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 4 (5): 529-33, 1995 Jul-Aug.
11. Bell DA, Taylor JA, Paulson DF, et al.: Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85 (14): 1159-64, 1993.
12. Lower GM Jr, Nilsson T, Nelson CE, et al.: N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71-9, 1979.
13. Cartwright RA, Glashan RW, Rogers HJ, et al.: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2 (8303): 842-5, 1982.
14. Hanke J, Krajewska B: Acetylation phenotypes and bladder cancer. J Occup Med 32 (9): 917-8, 1990.
15. Morrison AS, Cole P: Epidemiology of bladder cancer. Urol Clin North Am 3 (1): 13-29, 1976.
16. Steineck G, Plato N, Norell SE, et al.: Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 17 (3): 371-91, 1990.
17. King WD, Marrett LD: Case-control study of bladder cancer and chlorination by-products in treated water (Ontario, Canada). Cancer Causes Control 7 (6): 596-604, 1996.
18. Stadler WM: Molecular events in the initiation and progression of bladder cancer (review). Int J Oncol 3: 549-557, 1993.
19. Cole P, Hoover R, Friedell GH: Occupation and cancer of the lower urinary tract. Cancer 29 (5): 1250-60, 1972.
20. Cosyns JP: Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 26 (1): 33-48, 2003.
21. Chang CH, Wang YM, Yang AH, et al.: Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 21 (6): 441-8, 2001 Nov-Dec.
22. Kessler DA: Cancer and herbs. N Engl J Med 342 (23): 1742-3, 2000.
23. Liou SH, Lung JC, Chen YH, et al.: Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res 59 (7): 1481-4, 1999.
24. Moore LE, Smith AH, Hopenhayn-Rich C, et al.: Decrease in bladder cell micronucleus prevalence after intervention to lower the concentration of arsenic in drinking water. Cancer Epidemiol Biomarkers Prev 6 (12): 1051-6, 1997.
25. Sturgeon SR, Hartge P, Silverman DT, et al.: Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology 5 (2): 218-25, 1994.
26. Hamid R, Bycroft J, Arya M, et al.: Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol 170 (2 Pt 1): 425-7, 2003.
27. Delnay KM, Stonehill WH, Goldman H, et al.: Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 161 (4): 1106-8; discussion 1108-9, 1999.
28. Lucas SB: Squamous cell carcinoma of the bladder and schistosomiasis. East Afr Med J 59 (5): 345-51, 1982.
29. O'Keane JC: Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 319 (13): 871, 1988.
30. Tuttle TM, Williams GM, Marshall FF: Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient. J Urol 140 (5): 1009-11, 1988.
31. Durkee C, Benson R Jr: Bladder cancer following administration of cyclophosphamide. Urology 16 (2): 145-8, 1980.
32. Cohen SM, Garland EM, St John M, et al.: Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 52 (13): 3577-81, 1992.
33. Habs MR, Schmähl D: Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Cancer 51 (4): 606-9, 1983.
34. Duncan RE, Bennett DW, Evans AT, et al.: Radiation-induced bladder tumors. J Urol 118 (1 Pt 1): 43-5, 1977.
35. Sella A, Dexeus FH, Chong C, et al.: Radiation therapy-associated invasive bladder tumors. Urology 33 (3): 185-8, 1989.
36. Quilty PM, Kerr GR: Bladder cancer following low or high dose pelvic irradiation. Clin Radiol 38 (6): 583-5, 1987.
37. Buzzeo BD, Heisey DM, Messing EM: Bladder cancer in renal transplant recipients. Urology 50 (4): 525-8, 1997.
38. Kantor AF, Hartge P, Hoover RN, et al.: Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119 (4): 510-5, 1984.
39. Locke JR, Hill DE, Walzer Y: Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol 133 (6): 1034-5, 1985.
40. Fraumeni JF Jr, Thomas LB: Malignant bladder tumors in a man and his three sons. JAMA 201(7): 97-99, 1967.
41. Aherne G: Retinoblastoma associated with other primary malignant tumours. Trans Ophthalmol Soc U K 94(4): 938-944, 1974.
42. McCullough DL, Lamma DL, McLaughlin AP 3rd, et al.: Familial transitional cell carcinoma of the bladder. J Urol 113 (5): 629-35, 1975.
43. Lynch HT, Ens JA, Lynch JF: The Lynch syndrome II and urological malignancies. J Urol 143 (1): 24-8, 1990.
44. Kiemeney LA, Moret NC, Witjes JF, et al.: Familial aggregation of transitional cell carcinoma of the urinary tract. [Abstract] Proceedings of the American Urological Association 155(suppl): A-1520, 691a, 1996.
45. Shipley WU, Kaufman DS, McDougal WS: Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 1168-85.
46. Varkarakis MJ, Gaeta J, Moore RH, et al.: Superficial bladder tumor. Aspects of clinical progression. Urology 4 (4): 414-20, 1974.
47. Sultana SR, Goodman CM, Byrne DJ, et al.: Microscopic haematuria: urological investigation using a standard protocol. Br J Urol 78 (5): 691-6; discussion 697-8, 1996.
48. Khadra MH, Pickard RS, Charlton M, et al.: A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 163 (2): 524-7, 2000.
49. Carmack AJ, Soloway MS: The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology 67 (3 Suppl 1): 3-8; discussion 8-10, 2006.
50. Messing EM, Young TB, Hunt VB, et al.: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (3): 387-96; discussion 396-7, 1995.
51. Briggs NC, Young TB, Gilchrist KW, et al.: Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer 69 (6): 1445-51, 1992.
52. Lynch CF, Platz CE, Jones MP, et al.: Cancer registry problems in classifying invasive bladder cancer. J Natl Cancer Inst 83 (6): 429-33, 1991.
53. Saxman SB, Propert KJ, Einhorn LH, et al.: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (7): 2564-9, 1997.
54. Jewett HJ, Strong GH: Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 55: 366-372, 1946.
55. Kaye KW, Lange PH: Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 128 (1): 31-3, 1982.
56. Hopkins SC, Ford KS, Soloway MS: Invasive bladder cancer: support for screening. J Urol 130 (1): 61-4, 1983.
57. Holmäng S, Hedelin H, Anderström C, et al.: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153 (6): 1823-6; discussion 1826-7, 1995.
58. Prout GR Jr, Barton BA, Griffin PP, et al.: Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 148 (5): 1413-9, 1992.
59. Messing EM, Young TB, Hunt VB, et al.: Hematuria home screening: repeat testing results. J Urol 154 (1): 57-61, 1995.
60. Whelan P, Britton JP, Dowell AC: Three-year follow-up of bladder tumours found on screening. Br J Urol 72 (6): 893-6, 1993.
61. Mohr DN, Offord KP, Owen RA, et al.: Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 256 (2): 224-9, 1986.
62. Hiatt RA, Ordoñez JD: Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev 3 (5): 439-43, 1994 Jul-Aug.
63. Friedman GD, Carroll PR, Cattolica EV, et al.: Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Cancer Epidemiol Biomarkers Prev 5 (12): 993-6, 1996.
64. Messing EM, Young TB, Hunt VB, et al.: The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol 137 (5): 919-22, 1987.
65. Kiemeney LA, Coebergh JW, Koper NP, et al.: Bladder cancer incidence and survival in the south-eastern part of The Netherlands, 1975-1989. Eur J Cancer 30A (8): 1134-7, 1994.
66. Rife CC, Farrow GM, Utz DC: Urine cytology of transitional cell neoplasms. Urol Clin North Am 6 (3): 599-612, 1979.
67. Murphy WM, Rivera-Ramirez I, Medina CA, et al.: The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 158 (6): 2102-6, 1997.
68. Yamaguchi N, Tazaki H, Okubo T, et al.: Periodic urine cytology surveillance of bladder tumor incidence in dyestuff workers. Am J Ind Med 3 (2): 139-48, 1982.
69. Cartwright RA: Bladder cancer screening in the United Kingdom. J Occup Med 32 (9): 878-80, 1990.
70. Schulte PA: Screening for bladder cancer in high-risk groups: delineation of the problem. J Occup Med 32 (9): 789-92, 1990.
71. Cartwright RA, Gadian T, Garland JB, et al.: The influence of malignant cell cytology screening on the survival of industrial bladder cancer cases. J Epidemiol Community Health 35 (1): 35-8, 1981.
72. Thériault GP, Tremblay CG, Armstrong BG: Bladder cancer screening among primary aluminum production workers in Quebec. J Occup Med 32 (9): 869-72, 1990.
73. Hemstreet GP 3rd, Yin S, Ma Z, et al.: Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 93 (6): 427-36, 2001.
Get More Information From NCI
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615.
Changes To This Summary (03/13/2008)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Purpose of This PDQ Summary
Added this new section.
Description of Evidence
Updated incidence and mortality estimates for 2008 (cited American Cancer Society as reference 1).
Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English.
Additional PDQ Summaries
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Date last modified 2008-03-13